Research Library

open-access-imgOpen AccessIn vitro antibacterial activity of DU-6859a, a new fluoroquinolone
Takanori Nakane,
Shizuko Iyobe,
Koji Sato,
Susumu Mitsuhashi
Publication year1995
Publication title
antimicrobial agents and chemotherapy
Resource typeJournals
PublisherAmerican Society for Microbiology
The in vitro antibacterial activity of DU-6859a, a new fluoroquinolone, against a wide variety of clinical isolates was evaluated and compared with those of tosufloxacin, ofloxacin, ciprofloxacin, and sparfloxacin. DU-6859a showed potent broad-spectrum activity against gram-positive, gram-negative, and anaerobic bacteria, and its activity was greater than those of the control quinolones. By comparison of MICs at which 90% of strains are inhibited, DU-6859a had potent activity against bacteria resistant to the control quinolones. The time-killing curves of quinolones showed that the number of viable cells decreased rapidly during 2 to 4 of incubation, and regrowth was not seen even after 8 h incubation. At a concentration of four times the MIC, the frequencies of appearance of spontaneous mutants of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa resistant to DU-6859a were < or = 4.0 x 10(-9) to 1.9 x 10(-8). The 50% inhibitory concentrations of DU-6859a were 0.86 and 1.05 micrograms/ml for the supercoiling activities of DNA gyrases isolated from E. coli and P. aeruginosa, respectively. The rank order of the 50% inhibitory concentrations observed for both DNA gyrases roughly paralleled the MICs.
Subject(s)anaerobic bacteria , antibacterial activity , antibacterial agent , antibiotics , bacteria , biochemistry , biology , ciprofloxacin , dna , dna replication , dna supercoil , escherichia coli , gene , genetics , in vitro , microbiology and biotechnology , minimum inhibitory concentration , ofloxacin , pseudomonas aeruginosa , sparfloxacin , staphylococcus aureus
SCImago Journal Rank2.07

Seeing content that should not be on Zendy? Contact us.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here